Coronary stent implantation is superior to balloon angioplasty for chronic coronary occlusions
Six-year clinical follow-up of the GISSOC trial
Paolo Rubartelli, MD*,*,
Edoardo Verna, MD
,
Luigi Niccoli, MD
,
Corinna Giachero, MD*,
Marco Zimarino, MD
,
Guglielmo Bernardi, MD||,
Corrado Vassanelli, MD¶,
Luigi Campolo, MD#,
Eugenio Martuscelli, MD** Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche (GISSOC) Investigators
* Ospedale San Martino, Genoa, Italy
Ospedale di Circolo, Varese, Italy
Spedali Civili, Brescia, Italy
Università di Chieti, Chieti, Italy
|| Ospedale Santa Maria della Misericordia, Udine, Italy
¶ Università del Piemonte Orientale, Novara, Italy
# Casa di Cura Privata Villa Azzurra, Rapallo, Italy
** Policlinico Umberto I, Rome, Italy

View larger version (16K):
[in a new window]
|
Figure 1 Kaplan-Meier major adverse cardiac events (MACE)-free survival of patients assigned to stent implantation (solid line) or percutaneous transluminal coronary angioplasty (PTCA) (dashed line). The number of patients at risk for each time point is shown. MACE includes cardiac death, myocardial infarction, or target lesion revascularization.
|
|

View larger version (14K):
[in a new window]
|
Figure 2 Kaplan-Meier target lesion revascularization (TLR)-free survival of patients assigned to stent implantation (solid line) or percutaneous transluminal coronary angioplasty (PTCA) (dashed line). The number of patients at risk for each time point is shown.
|
|
Copyright © 2003 by the American College of Cardiology Foundation.